featured
Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide Alone as Maintenance Therapy After Autologous SCT in Patients With Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
Lancet Oncol 2023 Jan 12;[EPub Ahead of Print], D Dytfeld, T Wróbel, K Jamroziak, T Kubicki, P Robak, A Walter-Croneck, J Czyż, A Tyczyńska, A Druzd-Sitek, K Giannopoulos, A Nowicki, T Szczepaniak, A Łojko-Dankowska, M Matuszak, L Gil, B Puła, J Rybka, M Majcherek, L Usnarska-Zubkiewicz, Ł Szukalski, A Końska, JM Zaucha, J Walewski, D Mikulski, O Czabak, T Robak, OB Lahoud, JA Zonder, K Griffith, A Stefka, A Major, BA Derman, AJ JakubowiakFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.